Viatris VTRS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Developed Markets Segment | $8.68B+1.5% | $8.55B+1.2% | $8.45B-0.5% | $8.49B-2.3% | $8.69B-3.1% | |
| Emerging Markets Segment | $2.23B+0.6% | $2.22B+2.4% | $2.17B+1.7% | $2.13B-1.2% | $2.15B-4.7% | |
| Greater China | $2.46B+5.3% | $2.33B+2.2% | $2.28B+2.4% | $2.23B+2.3% | $2.18B+0.5% | |
| Japan, Australia and New Zealand Segment | $1.19B-0.3% | $1.2B-2.4% | $1.23B-3.0% | $1.27B-3.3% | $1.31B-3.0% | |
| Net Sales by Product | ||||||
| Brands | $9.4B+2.3% | $9.18B+2.0% | $9B+0.8% | $8.93B-0.9% | $9.01B-2.1% | |
| Celebrex ® | $276.6M+1.4% | $272.9M-0.3% | $273.8M-0.3% | $274.6M-0.8% | $276.8M-3.1% | |
| Creon ® | $380.8M+4.1% | $365.8M+2.4% | $357.3M+2.4% | $348.8M+3.9% | $335.6M+2.3% | |
| Dymista ® | $158.1M-3.4% | $163.6M-1.6% | $166.3M-5.5% | $176M-3.6% | $182.6M-2.9% | |
| Effexor ® | $260.4M+1.0% | $257.7M+1.4% | $254.1M+0.4% | $253.2M+0.2% | $252.8M0.0% | |
| EpiPen® Auto-Injectors | $474.1M+0.9% | $469.7M+1.3% | $463.8M+7.9% | $429.8M+5.2% | $408.5M+4.2% | |
| Generics | $5.12B+1.0% | $5.07B-0.1% | $5.07B-1.3% | $5.14B-2.6% | $5.27B-4.0% | |
| Lipitor | $1.62B+4.8% | $1.55B+1.4% | $1.53B+1.4% | $1.51B+2.7% | $1.47B-0.1% | |
| Lyrica ® | $495M+1.6% | $487M-1.5% | $494.2M-0.7% | $497.6M+0.8% | $493.8M-0.3% | |
| Norvasc | $747.6M+5.3% | $709.9M+1.3% | $700.9M+1.6% | $690.1M+3.1% | $669.3M-0.6% | |
| Viagra ® | $404.7M-0.9% | $408.2M+4.0% | $392.6M+1.3% | $387.6M-1.5% | $393.4M-0.6% | |
| Xalabrands | $160.5M+1.3% | $158.4M+3.2% | $153.5M-1.7% | $156.1M-3.0% | $161M-3.2% | |
| Xanax ® | $142.4M+1.8% | $139.9M+2.2% | $136.9M-3.1% | $141.3M-1.1% | $142.8M-1.5% | |
| Yupelri ® | $271.1M+1.6% | $266.9M+1.5% | $262.9M+3.6% | $253.7M+5.0% | $241.6M+1.3% | |
| Zoloft ® | $267.3M+4.9% | $254.9M+3.5% | $246.3M+2.6% | $240.1M+0.9% | $237.9M+0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Viatris break its business down?
- Viatris (VTRS) reports net sales by business across 4 parts — Developed Markets Segment, Emerging Markets Segment, Greater China and Japan, Australia and New Zealand Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Viatris's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Viatris's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
